Vanda Pharmaceuticals Reports Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
- Novo Nordisk shares drop as investor event disappoints
Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 10c
November 2, 2016 5:01 PM EDTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of ($0.01), $0.10 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $38.5 million versus the consensus estimate of $38.05 million.
Cash, cash equivalents and marketable securities (Cash) were $142.6 million as of September 30, 2016, representing... More
